Sanam Shafaattalab

Sanam Shafaattalab

Auto-generated profile, based on publicly available information

Sanam Shafaattalab

A2 Biotherapeutics Inc, Agoura Hills, California, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
YSYu Patrick Shi
Yu Patrick Shi
ZPZhaoKai Pang
ZhaoKai Pang
RVRavichandra Venkateshappa
Ravichandra Venkateshappa
MGMarvin Gunawan
Marvin Gunawan
JKJacob Kemp
Jacob Kemp
TCThomas W. Claydon
Thomas W. Claydon
Human ether-à-go-go related gene (hERG) K+ channels are important in cardiac repolarization, and their dysfunction causes prolongation of the ventricular action potential, long QT syndrome, and arrhythmia. As such, approaches to augment hERG channel function, such as activator compounds, have been of significant interest due to their marked therapeutic potential. Activator compounds that hinder channel inactivation abbreviate action potential duration (APD) but carry risk of overcorrection leading to short QT syndrome. Enhanced risk by overcorrection of the APD may be tempered by activator-induced increased refractoriness; however, investigation of the cumulative effect of hERG activator compounds on the balance of these effects in whole organ systems is lacking. Here, we have investigated the antiarrhythmic capability of a hERG activator, RPR260243, which primarily augments channel function by slowing deactivation kinetics in ex vivo zebrafish whole hearts. We show that RPR260243 abbreviates the ventricular APD, reduces triangulation, and steepens the slope of the electrical restitution curve. In addition, RPR260243 increases the post-repolarization refractory period. We provide evidence that this latter effect arises from RPR260243-induced enhancement of hERG channel-protective currents flowing early in the refractory period. Finally, the cumulative effect of RPR260243 on arrhythmogenicity in whole organ zebrafish hearts is demonstrated by the restoration of normal rhythm in hearts presenting dofetilide-induced arrhythmia. These findings in a whole organ model demonstrate the antiarrhythmic benefit of hERG activator compounds that modify both APD and refractoriness. Furthermore, our results demonstrate that targeted slowing of hERG channel deactivation and enhancement of protective currents may provide an effective antiarrhythmic approach. NEW & NOTEWORTHY hERG channel dysfunction causes long QT syndrome and arrhythmia. Activator compounds have been of significant interest due to their therapeutic potential. We used the whole organ zebrafish heart model to demonstrate the antiarrhythmic benefit of the hERG activator, RPR260243. The activator abbreviated APD and increased refractoriness, the combined effect of which rescued induced ventricular arrhythmia. Our findings show that the targeted slowing of hERG channel deactivation and enhancement of protective currents caused by the RPR260243 activator may provide an effective antiarrhythmic approach.

18 March 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SSSanam Shafaattalab
Sanam Shafaattalab
ALAlison Yueh Li
Alison Yueh Li
ELEric Lin
Eric Lin
CSCharles M. Stevens
Charles M. Stevens
LDLaura J. Dewar
Laura J. Dewar
GTGlen Findlay Tibbits
Glen Findlay Tibbits
Significance: A major aim of this study was to develop an experimental pipeline for the analysis and assessment of variants potentially causal in sudden cardiac death of infants (SCDI). The TNNI R37C +/− variant in this study was reliably and reproducibly disruptive to the normal physiology, in contrast to that in isogenic controls, across a battery of in silico and in vitro assays. This strengthens the evidence of pathogenicity and implicates a neonatal gene paralog encoding a sarcomeric contractile protein as having likely contributed to SCDI through a proarrhythmic pathway. This platform has the potential to be applied broadly as part of a standardized and clinically relevant death investigation in cases of SCDI where novel variants are identified.

21 October 2025 in Circulation
Verified
Journal Article
Closed access
FLFujian Lu
Fujian Lu
ZWZexuan Wu
Zexuan Wu
SCShaopeng Chi
Shaopeng Chi
YWYangong Wang
Yangong Wang
APAnna Ponek
Anna Ponek
WPWilliam Pu
William Pu

12 September 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
SSSanam Shafaattalab
Sanam Shafaattalab
APAlexander Partin
Alexander Partin
AWAaron Winters
Aaron Winters
RBRichele Bruno
Richele Bruno
VSVasantika Suryawanshi
Vasantika Suryawanshi
AKAlexander Kamb
Alexander Kamb
Background: On-target, off-tumor toxicity is a recurring challenge for solid tumor therapeutics targeted to antigens preferentially expressed on malignant cells. Prostate-specific membrane antigen (PSMA) is a tumor-associated antigen that is expressed on the healthy prostate and is generally upregulated in prostate cancer. It is also detected via RNA-Seq in the central and peripheral nervous system (CNS and PNS) at levels that can exceed those in the prostate itself. The CNS/PNS expression of PSMA has been largely ignored in the oncology field, and it is possible that therapeutics targeting PSMA have limited access to antigens in the nervous system. However, many PSMA-targeted therapeutics that are active in the clinic induce substantial neurotoxicity, in some cases, even treatment-associated fatalities. Methods: To protect PSMA-expressing neural tissues from on-target, off-tumor toxicity, we applied a synthetic cellular NOT gate that uses a LIR-1-based inhibitory receptor. We selected the NOT gate target antigen by searching genomic databases for a surface protein co-expressed with PSMA in the brain. Results: Here, we demonstrate that proteolipid protein 1 (PLP1), a protein expressed on the surface of oligodendrocytes and Schwann cells, is co-expressed with PSMA in the CNS and PNS. A NOT gate construct (PSMA | PLP1 Tmod) protects human oligodendrocytes in vitro from the cytotoxicity of a PSMA CAR. Though PSMA is not expressed in mouse brains at high levels, we show that PLP1 CARs induce toxicity in mice, consistent with the possibility that CNS/PNS expression of the target of an immunotherapeutic poses a serious risk. This toxicity is mitigated by a Tmod construct (PLP1 | PLP1), in which a PLP1 CAR substitutes for a PSMA CAR, a proof of principle that circumvents the problematic expression pattern of PSMA in the mouse. Conclusions: Together, these findings not only highlight some of the potential risks and benefits of immunotherapy for solid tumors regarding antigens expressed in the brain, but also suggest a specific solution for PSMA CAR-Ts.